Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results

Eagle Pharmaceuticals (EGRX) PT Raised to $84 at RBC Capital

August 8, 2018 8:32 AM EDT

RBC Capital raised its price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $84.00 (from $74.00) while maintaining a Outperform rating.

... More

Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 15c, Revenues Beat

August 7, 2018 6:52 AM EDT

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.95, $0.15 better than the analyst estimate of $0.80. Revenue for the quarter came in at $59.3 million versus the consensus estimate of $51.23 million.

Total revenue for the second quarter of 2018 was $59.3 million, compared to $50.1 million in the second quarter of 2017;Eagle launched bendamustine hydrochloride 500ml solution (Big Bag) on May 15, 2018 and Big Bag product sales were $8.1 million in the second quarter of 2018;Q2 2018 Ryanodex product sales were $7.2 million, up 38% compared to Q2 2017;Q2 2018 net income was $2.7 million, or $0.18 per basic and $0.17 per diluted... More